AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05620654
Drug: Hyperthermic Intraperitoneal Paclitaxel Combined With Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The starting dose for paclitaxel was 175 mg/m2, with escalation in 25 mg/m2 increments until the MTD was determined or the maximum dose level of 225 mg/m2 was reached. The target dose-limiting toxicity (DLT) rate was 25%, and the total sample size was 30 patients. HIPEC was delivered immediately following the debulking surgery using the closed technique with a target temperature of 43 ℃ for 90 minutes.
Trial: NCT04764084
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Niraparib 100mg or 200mg, PO, qd，d1-d21
Trial: NCT04764084
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib 12mg, PO, qd，d1-d14
Trial: NCT05207722
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg on Day 1 of each 3-week cycle as an IV infusion.
Trial: NCT05207722
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8 mg/kg loading dose and then 6 mg/kg maintenance dose administered IV on day 1 of each 3-week cycle.
Trial: NCT05207722
Drug: Recombinant Human Interleukin-2
RxNorm normalized name: Recombinant human interleukin-2
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 million (M) international units (IU) of rhIL-2 administered subcutaneously (SC) on each CYNK-101 infusion day.
Trial: NCT05207722
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine: 30 mg/m2 administered IV as part of a 3-day lymphodepletion regimen.
Trial: NCT05207722
Drug: Mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MESNA: shall be administered as part of a 3-day lymphodepletion regimen for the inhibition of hemorrhagic cystitis induced by cyclophosphamide. Route of administration, dosage, and frequency of Mesna should be based on institutional standards.
Trial: NCT04985266
Drug: Palbociclib 125Mg Tab
RxNorm normalized name: PALBOCICLIB 125MG TAB
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib Tablets, 125 mg orally once daily, beginning on Cycle 1, on Days 1-21 of each 28-day cycle.
Trial: NCT04985266
Drug: Fulvestrant injection
RxNorm normalized name: Fulvestrant Injection
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant Intramuscular injections, 500 mg as two injection of 250mg fulvestrant in 5ml solution at each visit. No fulvestrant dose reductions are permitted. Administered on days 1, 15 (plus or minus 3 days), 29 (plus or minus 3 days), and every 28 (plus or minus 3 days) days thereafter.
Trial: NCT04985266
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As per clinical guidelines
Trial: NCT04985266
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As per clinical guidelines
Trial: NCT04985266
Drug: Exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As per clinical guidelines
Trial: NCT04985266
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As per clinical guidelines
Trial: NCT06167642
Drug: Ofatumumab
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ofatumumab therapy is part of the patient's clinical care and is not given as part of the study
Trial: NCT05308901
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg IV every 3 weeks for a maximum of 2 years.
Trial: NCT05308901
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 20 mg daily for a maximum of 2 years.
Trial: NCT05888103
Drug: Inclisiran
RxNorm normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran\*) in 1.5 mL
Trial: NCT05888103
Drug: Matching Placebo for Inclisiran
RxNorm normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Matching s.c. placebo in 1.5 mL
Trial: NCT06107335
Drug: Human Albumin (colloid)
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid replacement will be achieved with colloid (5% albumin infusion). A bolus infusion of up to 500 milliliters (mL) of 5% Albumin will be administered prior to the placement of neuraxial anesthesia. If stroke volume variation (SVV) drops to less than 13% during the infusion of albumin, the infusion will be halted. At the completion of the placement of the spinal/combined spinal-epidural (CSE) anesthesia, study participants will receive the remaining albumin infusion if it was initially halted and SVV increases back to \>13% during the procedure (to a total maximum of 500 mL albumin for the entire procedure).
Trial: NCT06107335
Drug: Lactated Ringer's Injection (crystalloid)
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluid restriction will be achieved with crystalloid (lactated ringer's injection) administered at a keep-the-vein-open (KVO) rate of 75 milliliters per hour (mL/hr), administered during the procedure.
Trial: NCT06470373
Drug: RBS-001 Solution for intravitreal injection
RxNorm normalized name: Rubidium Rb-82
DrugBank: BS-001 (DB17415)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer 2 mg/eye (50 uL/eye) per dose of the IP via IVT to the subjects' study eye
Trial: NCT06730516
Drug: Latanoprost (Xalatan)
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: latanoprost 0.005
Trial: NCT06730516
Drug: Brimonidine 0.2 %
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brimonidine0.2
Trial: NCT05144243
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet: Oral
Trial: NCT05144243
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous Injection (SC)
Trial: NCT00001064
Drug: Allogenic Dendritic Cells
RxNorm normalized name: Allogeneic human mesenchymal stem cell
DrugBank: Remestemcel-L (DB13973)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05194189
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 g vitamin C (48 ml) will be intravenously injected by a infusion pump every 12 h for 4 days or at ICU discharge
Trial: NCT00357045
Drug: Paroxetine
RxNorm normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05636306
Drug: NoNO-42
RxNorm normalized name: Nonoxynol 9
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single intravenous infusion weight-based dose of NoNO-42 administered over 10±1 minute
Trial: NCT05057819
Drug: Empagliflozin 25 MG
RxNorm normalized name: empagliflozin 25 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment naive patients with bariatric bypass surgery will be given oral empagliflozin 25mg once daily for 20 days
Trial: NCT01224652
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel, 70 mg/m2 will be administered as an intravenous (IV) infusion over 1 hour on Days 1, 8 and 15 of a 28-day cycle
Trial: NCT01224652
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: irinotecan 150 mg/m2 will be administered as an intravenous (IV) infusion over 1 hour on Days 1 and 15 of a 28-day cycle
Trial: NCT06081959
Drug: Eribulin
RxNorm normalized name: Eribulin
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1.4 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle
Trial: NCT06081959
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2, IV infusion on day 1 and Day 8 of each 21day cycle
Trial: NCT06081959
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle
Trial: NCT05983939
Drug: PIPE-791
RxNorm normalized name: Horse-pipes Top
DrugBank: Equisetum arvense top (DB14349)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single and multiple ascending oral doses of PIPE-791 tablets.
Trial: NCT04761159
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Different mixture of ketamin-propofol will apply for anesthesia induction.
Trial: NCT05436678
Drug: PrimeC 748 mg
RxNorm normalized name: trenbolone
DrugBank: Trenbolone (DB11551)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PrimeC is an extended release formulation of a fixed dose combination of ciprofloxacin and celecoxib
Trial: NCT05436678
Drug: Ciprofloxacin 750 MG
RxNorm normalized name: ciprofloxacin 750 MG
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin
Trial: NCT05764746
Drug: Artemether-lumefantrine and Amodiaquine Drug Combination
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AL and AQ will be given together for three days then followed by placebo for three days
Trial: NCT05764746
Drug: Artemether-lumefantrine then Artesunate amodiaquine
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AL will be given twice a day for three days then followed by artesunate amodiaquine once a day for three days
Trial: NCT04785261
Drug: Methylhydroxypropylcellulose
RxNorm normalized name: hydroxypropylcellulose
DrugBank: Propyl acetate (DB01670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-2 drips each time, every 4 hours, for 12 weeks.
Trial: NCT04785261
Drug: Carbomer
RxNorm normalized name: carbomer
DrugBank: Carbomer (DB15649)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drip each time, at bedtime, for 12 weeks.
Trial: NCT04521647
Drug: Nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive two nicotine concentrations via e-cigarettes. Each exposure will be 10 3-sec puffs and ad libitum use
Trial: NCT05364073
Drug: Furmonertinib
RxNorm normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furmonertinib tablet
Trial: NCT05459974
Drug: Colchicine 0.6 mg
RxNorm normalized name: colchicine 0.6 MG
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine 0.6 mg once daily for 30 days after the atrial fibrillation ablation
Trial: NCT04662255
Drug: Pirtobrutinib
RxNorm normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT04662255
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral
Trial: NCT04662255
Drug: Acalabrutinib
RxNorm normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral
Trial: NCT04662255
Drug: Zanubrutinib
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral
Trial: NCT06263517
Drug: Clodronate
RxNorm normalized name: Clodronate
DrugBank: Clodronic acid (DB00720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For Arm 1, patients will be treated with intra articular clodronate 2 mg/2 ml from Baseline to Week 3
Trial: NCT06263517
Drug: Clodronate
RxNorm normalized name: Clodronate
DrugBank: Clodronic acid (DB00720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For Arm 2, patients will be treated with intra articular clodronate 5 mg/2 ml from Baseline to Week 3
Trial: NCT06263517
Drug: Clodronate
RxNorm normalized name: Clodronate
DrugBank: Clodronic acid (DB00720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For Arm 3, patients will be treated with intra articular clodronate 10 mg/2 ml from Baseline to Week 3
Trial: NCT04984759
Drug: Primaquine
RxNorm normalized name: Primaquine
DrugBank: Primaquine (DB01087)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Primaquine GPO® (Government Pharmaceutical Organization (GPO), Thailand) 0.5 mg/kg will be given once daily with food for 14 days. This is the dose recommended for radical cure of P. vivax in tropical areas with high rates of relapse, such as the study design setting. Doses will be directly supervised (DOT).
Trial: NCT04984759
Drug: Tafenoquine
RxNorm normalized name: tafenoquine
DrugBank: Tafenoquine (DB06608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tafenoquine (Kodatef, Biocelect Pty Ltd.) 300 mg will be given as a directly observed single dose with food. This is the standard dose recommended globally for radical cure of P. vivax.
Trial: NCT05351788
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle（AUC 5)
Trial: NCT05998317
Drug: At-night Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in the intervention group will receive intravenous 8 mg dexamethasone at night before surgery. The time of dexamethasone administration will be recorded. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensation in injection.
Trial: NCT05998317
Drug: At-induction Dexamethasone
RxNorm normalized name: dexamethasone Injection
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in the control group will receive intravenous 8 mg dexamethasone just before or at the induction of anesthesia. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensation in injection.
Trial: NCT05351788
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (75mg/m²)
Trial: NCT06144723
Drug: HS-20105
RxNorm normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously every 21 days.
Trial: NCT04340258
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 200 mg will be administered as a 30-minute IV infusion every 3 weeks. The drug will be infused through a peripheral line or an indwelling catheter. The first dose will be given 2 weeks prior to surgery. Post-surgery, pembrolizumab will be started between 2 and 6 weeks and will continue every 3 weeks for a duration of 6 months. Study Drug may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons. The Investigator's Brochure contains specific instructions for the preparation of the standard of care pembrolizumab infusion fluid.
Trial: NCT05213585
Drug: Ivermectin cream
RxNorm normalized name: Ivermectin Cream
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical application of ivermectin cream to eyelashes of treatment eye.
Trial: NCT05401214
Drug: Niraparib plus Abiraterone Acetate (Nira/AA) combination
RxNorm normalized name: abiraterone acetate / niraparib Pill
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nira 100 milligrams (mg)/AA 500 mg combination will be administered orally as immediate-release film coated tablets.
Trial: NCT05401214
Drug: Prednisone/Prednisolone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone/Prednisolone 10 mg will be administered orally.
Trial: NCT05765084
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab (1200 mg) will be administered on day 0 of each 3-weekly platinum/pemetrexed-based chemotherapy cycle. Atezolizumab should be administered before chemotherapy administration as an IV infusion over 60 (±15) minutes. If the first infusion is tolerated, all subsequent infusions may bedelivered over 30 (±10) minutes. Additional atezolizumab treatment (1680 mg) after the study treatment schedule can be administered (optional) at 4-weekly intervals (± 1 week) as an IV infusion over 30-60 minutes.
Trial: NCT05765084
Drug: Platinum/pemetrexed based chemotherapy
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: On the first day of each cycle (day 0), pemetrexed 500 mg/m2 should be administered as intravenous (IV) infusion over 10 minutes, followed by cisplatin 75 mg/m2 as IV over approximately 2 hours. The actual doses of the drugs to be administered to patients will be determined by calculating the patient's body surface area at the beginning of each cycle. For ease of dose administration, the protocol allows ± 5% variance in the calculated total dose per infusion. If deemed necessary, the treating physician can decide to replace cisplatin by carboplatin. In that case, carboplatin will be delivered to an area under the concentration-time curve (AUC) of 5 as an IV infusion over 1 hour.
Trial: NCT06114537
Drug: Acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The used intervention in this study is acetazolamide, which belongs to a class of drugs known as carbonic anhydrase inhibitors and has been used with other medications to treat high ocular pressure due to certain types of glaucoma~Patients in the treatment group will receive 250 milligrams of oral acetazolamide twice daily for 16 weeks.~Patients randomized to the treatment group will switch to 125 milligrams of oral acetazolamide twice daily for another four weeks when the central foveal thickness (CFT) on OCT is reduced by ≥25% at the evaluation visit at 16 weeks after the baseline visit. These patients will continue with this dose till the end of the study when the CFT on OCT is stable or further reduced. If the CFT on OCT has increased, they switch back to 250 milligrams of oral acetazolamide twice daily for another 12 weeks.
Trial: NCT05344209
Drug: Sagramostim
RxNorm normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: for stimulation of local dendritic cell population to take up the vaccine and to mature into professional APCs
Trial: NCT05102123
Drug: Cytisine
RxNorm normalized name: Cytisine
DrugBank: Cytisine (DB09028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Listed as a natural health product in Canada, cytisine is utilized to aid in smoking cessation
Trial: NCT06404736
Drug: Bispecific antibody (bsAb) targeting PD-1 and CLTA-4
RxNorm normalized name: Anti-pd-1/tim-3 bispecific antibody ro7121661
DrugBank: Lomvastomig (DB19060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QL1706 is a novel bispecific combination antibody composed of a recombinant humanized IgG4 monoclonal antibody targeting human PD-1 (programmed cell death protein 1) (PSB103) and a recombinant humanized IgG1 monoclonal antibody targeting human CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) (PSB105). Both antibodies have undergone engineering modifications to introduce mutations facilitating their correct assembly and preventing mispairing, and are expressed in the same cell line at a predetermined ratio (approximately 2:1).
Trial: NCT06404736
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin is a chemotherapy medication belonging to the platinum-based class of drugs, commonly used in the treatment of various cancers, including ovarian cancer, lung cancer, and bladder cancer. It functions by forming DNA adducts, disrupting DNA replication and transcription processes in cancer cells, ultimately leading to cell death. Despite its efficacy, carboplatin can cause side effects such as nausea, vomiting, and bone marrow suppression.
Trial: NCT04970602
Drug: Methylene Blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once the patient meets inclusion criterial, the interventional group will receive 2mg/kg methylene blue infusion within 20min, followed by 0.5mg/kg/h for 4 hours.
Trial: NCT05059145
Drug: Chlorhexidine Gluconate
RxNorm normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal cream 1%
Trial: NCT05059145
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg oral capsule
Trial: NCT06278727
Drug: angiotensin-converting enzyme inhibitors/angiotensin II receptor blocker/angiotensin receptor-neprilysin inhibitor
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Guideline-directed Medical Therapy (GDMT) includes those 4 drugs, and only taking at least 3 drugs could be recognized as GDMT.
Trial: NCT04990037
Drug: CAN04
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously
Trial: NCT05280509
Drug: TL-895
RxNorm normalized name: TL-895
DrugBank: TL-895 (DB16471)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.